Member Medication Recalls and Notices

Below are recent nationwide medication recalls and notices.

If you are taking any of the products below:

  • Please talk to your doctor immediately to consider changing to a different medication for your condition.
  • Return the recalled medication to your pharmacy.
  • You can contact your doctor if you have questions about these recalls and notices.

Medication Recalls

  • CHANTIX
    Recalled Medication: Chantix, Varenicline tablets
    Manufacturer: Pfizer
    Recall Date: 09/16/2021
    Reason: N-nitroso-varenicline above acceptable daily intake level
    FDA Notice
  • CHANTIX® (Varenicline) Tablets
    Recalled Medication: Chantix
    Manufacturer: Pfizer
    Recall Date: 07/16/2021
    Reason: N-Nitroso Varenicline content above ADI level
    FDA Notice
  • Recalled Medication: Paroex Chlorhexidine Gluconate Oral Rinse, 4 oz and 16 oz
    Manufacturer: Sunstar Americas, Inc.
    Recall Date: 12/28/2020
    Reason: Potential contamination with Burkholderia lata
    FDA Notice
  • Recalled Medication: Metformin Hydrochloride Extended-Release Tablets, USP 500mg & 750mg
    Manufacturer: Marksans Pharma Limited
    Recall Date: 10/05/2020
    Reason: Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
    FDA Notice
  • Recalled Medication: Albuterol Sulfate Inhalation Aerosol
    Manufacturer: Catalent Pharma Solutions for Perrigo Pharmaceutical Company
    Recall Date: 09/21/2020
    Reason: Due to possible clogging of the inhaler resulting in patients not receiving enough or any medicine.
    FDA Notice
  • Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg
    Manufacturer: Bayshore Pharmaceuticals, LLC
    Recall Date: 08/19/2020
    Reason: Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
    FDA Notice 
  • DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, STIMATE® Nasal Spray 1.5 mg/mL
    Manufacturer: Ferring Pharmaceuticals US
    Recall Date: 08/05/2020
    Reason: These products are being recalled due to superpotency or amounts of desmopressin higher than specified.
    FDA Notice
  • Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg
    Manufacturer: Lupin Pharmaceuticals, Inc.
    Recall Date: 07/08/2020
    Reason: Due to the detection of N-Nitrosodimethylamine (NDMA).
    FDA Notice
  • Metformin Hydrochloride Extended-Release Tablets USP, 750mg
    Manufacturer: Granules Pharmaceuticals, Inc.
    Recall Date: 07/03/2020
    Reason: Due to the detection of N-Nitrosodimethylamine (NDMA).
    FDA Notice
  • Metformin Hydrochloride Extended-Release Tablets, USP 500mg and 750mg
    Manufacturer: Amneal Pharmaceuticals LLC
    Recall Date: 05/29/2020
    Reason: Due to detection of N-Nitrosodimethylamine (NDMA).
    FDA Notice
  • Metformin Hydrochloride Extended-Release Tablets, USP 500mg
    Manufacturer: Apotex Corp.
    Recall Date: 05/27/2020
    Reason: Due to detection of N-Nitrosodimethylamine (NDMA).
    FDA Notice
  • All Ranitidine Products (Zantac)
    Manufacturer: All
    Recall Date: 04/01/2020
    Reason: Ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) which is a probable human carcinogen (a substance that could cause cancer).
    FDA Notice
  • Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL
    Manufacturer: Amneal Pharmaceuticals, LLC
    Recall Date: 11/08/2019
    Reason: Due to potential N-Nitrosodimethylamine (NDMA) amounts being above levels established by the FDA.
    FDA Notice
  • Ranitidine Tablets 150mg, Ranitidine Capsules 150 mg, Ranitidine Capsules 300 mg and Ranitidine Syrup 15 mg/mLRanitidine Tablets, Capsules, and Syrup
    Manufacturer: Aurobindo Pharma USA, Inc.
    Recall Date: 11/06/2019
    Reason: Due to the detection of Nitrosodimethylamine (NDMA) impurity.
    FDA Notice
  • Ranitidine Syrup (Oral Solution, USP), 15 mg/mL
    Manufacturer: Lannett Company, Inc.
    Recall Date: 10/25/2019
    Reason: Due to levels of N-Nitrosodimethylamine (NDMA) being above the levels recently established by the FDA.
    FDA Notice
  • Ranitidine Tablets & Capsules
    Manufacturer: Dr. Reddy’s Laboratories Ltd.
    Recall Date: 10/23/2019
    Reason: Contamination with N-Nitrosodimethylamine (NDMA) above the levels established by the FDA.
    FDA Notice
  • Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg
    Recall Date: 06/26/2019
    Manufacturer: Macleods Pharmaceuticals, Ltd.
    Reason: Detection of trace amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the interim acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg
    Recall Date: 02/22/2019
    Manufacturer: Macleods Pharmaceuticals, Ltd.
    Reason: Detection of trace amounts of an unexpected impurity (NDEA) above the interim acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
    Recall Date: 01/22/19
    Manufacturer: Torrent Pharmaceuticals Limited
    Reason: Detection of trace amounts of an N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Irbesartan and Irbesartan HCTZ Tablets
    Recall Date: 01/18/2019
    Manufacturer: Prinston Pharmaceutical Inc. dba Solco Healthcare LLC
    Reason: Detection of trace amount of N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
    FDA Notice
  • Valsartan and Valsartan-HCTZ Tablets, USP
    Recall Date: 07/18/2018
    Manufacturers: Prinston Pharmaceuticals, and TEVA Pharmaceuticals.
    Reason: It has been found that the recalled products for impurity detected. This may cause unexpected health risks.
    FDA Notice – Prinston Pharmaceuticals
    FDA Notice – TEVA Pharmaceuticals

Medication Notices

  • Coumadin
    Notification Date: 06/01/2020
    Discontinuation of Sale and Distribution: This voluntary action is the result of an unexpected manufacturing issue that cannot be resolved and is not the result of any quality, safety or efficacy issue regarding the product.
    Official Notice
  • Lunesta (eszopiclone), Sonata (zaleplon), Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist (zolpidem)
    Notification Date: 04/30/2019
    Certain Prescription Insomnia Medicines: New Boxed Warning – Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake
    FDA Notice